Cargando…

The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density

OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DX...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, A., Cobb, J., Hansen, U., Bhattacharya, R., Reinhard, C., Vo, N., Atwood, R., Li, J., Karunaratne, A., Wiles, C., Abel, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670367/
https://www.ncbi.nlm.nih.gov/pubmed/29066534
http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1
_version_ 1783276011247370240
author Jin, A.
Cobb, J.
Hansen, U.
Bhattacharya, R.
Reinhard, C.
Vo, N.
Atwood, R.
Li, J.
Karunaratne, A.
Wiles, C.
Abel, R.
author_facet Jin, A.
Cobb, J.
Hansen, U.
Bhattacharya, R.
Reinhard, C.
Vo, N.
Atwood, R.
Li, J.
Karunaratne, A.
Wiles, C.
Abel, R.
author_sort Jin, A.
collection PubMed
description OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DXA) scanning may show a gain in bone density, the impact of this class of drug on mechanical properties remains unclear. We therefore sought to quantify the mechanical strength of bone treated with BP (oral alendronate), and correlate data with the microarchitecture and density of microcracks in comparison with untreated controls. METHODS: Trabecular bone from hip fracture patients treated with BP (n = 10) was compared with naïve fractured (n = 14) and non-fractured controls (n = 6). Trabecular cores were synchrotron scanned and micro-CT scanned for microstructural analysis, including quantification of bone volume fraction, microarchitecture and microcracks. The specimens were then mechanically tested in compression. RESULTS: BP bone was 28% lower in strength than untreated hip fracture bone, and 48% lower in strength than non-fractured control bone (4.6 MPa vs 6.4 MPa vs 8.9 MPa). BP-treated bone had 24% more microcracks than naïve fractured bone and 51% more than non-fractured control (8.12/cm(2) vs 6.55/cm(2) vs 5.25/cm(2)). BP and naïve fracture bone exhibited similar trabecular microarchitecture, with significantly lower bone volume fraction and connectivity than non-fractured controls. CONCLUSION: BP therapy had no detectable mechanical benefit in the specimens examined. Instead, its use was associated with substantially reduced bone strength. This low strength may be due to the greater accumulation of microcracks and a lack of any discernible improvement in bone volume or microarchitecture. This preliminary study suggests that the clinical impact of BP-induced microcrack accumulation may be significant. Cite this article: A. Jin, J. Cobb, U. Hansen, R. Bhattacharya, C. Reinhard, N. Vo, R. Atwood, J. Li, A. Karunaratne, C. Wiles, R. Abel. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 2017;6:602–609. DOI: 10.1302/2046-3758.610.BJR-2016-0321.R1.
format Online
Article
Text
id pubmed-5670367
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-56703672017-11-15 The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density Jin, A. Cobb, J. Hansen, U. Bhattacharya, R. Reinhard, C. Vo, N. Atwood, R. Li, J. Karunaratne, A. Wiles, C. Abel, R. Bone Joint Res Research OBJECTIVES: Bisphosphonates (BP) are the first-line treatment for preventing fragility fractures. However, concern regarding their efficacy is growing because bisphosphonate is associated with over-suppression of remodelling and accumulation of microcracks. While dual-energy X-ray absorptiometry (DXA) scanning may show a gain in bone density, the impact of this class of drug on mechanical properties remains unclear. We therefore sought to quantify the mechanical strength of bone treated with BP (oral alendronate), and correlate data with the microarchitecture and density of microcracks in comparison with untreated controls. METHODS: Trabecular bone from hip fracture patients treated with BP (n = 10) was compared with naïve fractured (n = 14) and non-fractured controls (n = 6). Trabecular cores were synchrotron scanned and micro-CT scanned for microstructural analysis, including quantification of bone volume fraction, microarchitecture and microcracks. The specimens were then mechanically tested in compression. RESULTS: BP bone was 28% lower in strength than untreated hip fracture bone, and 48% lower in strength than non-fractured control bone (4.6 MPa vs 6.4 MPa vs 8.9 MPa). BP-treated bone had 24% more microcracks than naïve fractured bone and 51% more than non-fractured control (8.12/cm(2) vs 6.55/cm(2) vs 5.25/cm(2)). BP and naïve fracture bone exhibited similar trabecular microarchitecture, with significantly lower bone volume fraction and connectivity than non-fractured controls. CONCLUSION: BP therapy had no detectable mechanical benefit in the specimens examined. Instead, its use was associated with substantially reduced bone strength. This low strength may be due to the greater accumulation of microcracks and a lack of any discernible improvement in bone volume or microarchitecture. This preliminary study suggests that the clinical impact of BP-induced microcrack accumulation may be significant. Cite this article: A. Jin, J. Cobb, U. Hansen, R. Bhattacharya, C. Reinhard, N. Vo, R. Atwood, J. Li, A. Karunaratne, C. Wiles, R. Abel. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res 2017;6:602–609. DOI: 10.1302/2046-3758.610.BJR-2016-0321.R1. 2017-11-04 /pmc/articles/PMC5670367/ /pubmed/29066534 http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1 Text en © 2017 Jin et al. This is an open-access article distributed under the terms of the Creative Commons Attributions licence (CC-BY-NC), which permits unrestricted use, distribution, and reproduction in any medium, but not for commercial gain, provided the original author and source are credited.
spellingShingle Research
Jin, A.
Cobb, J.
Hansen, U.
Bhattacharya, R.
Reinhard, C.
Vo, N.
Atwood, R.
Li, J.
Karunaratne, A.
Wiles, C.
Abel, R.
The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title_full The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title_fullStr The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title_full_unstemmed The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title_short The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
title_sort effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5670367/
https://www.ncbi.nlm.nih.gov/pubmed/29066534
http://dx.doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1
work_keys_str_mv AT jina theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT cobbj theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT hansenu theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT bhattacharyar theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT reinhardc theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT von theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT atwoodr theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT lij theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT karunaratnea theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT wilesc theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT abelr theeffectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT jina effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT cobbj effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT hansenu effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT bhattacharyar effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT reinhardc effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT von effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT atwoodr effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT lij effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT karunaratnea effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT wilesc effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity
AT abelr effectoflongtermbisphosphonatetherapyontrabecularbonestrengthandmicrocrackdensity